The launch of monoclonal antibody (MAb) immune checkpoint inhibitors (ICIs) in the past decade has been game changing and provided new treatment options across the spectrum of solid tumor types and hematological cancers.
However, ICIs are limited by the fact that they target one singular pathway to mediate T-cell cytotoxicity, which means patient...